- Home
- NTCT vs TSHA Comparison
NTCT vs TSHA Comparison
Compare NTCT & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTCT
- TSHA
- Stock Information
- Founded
- NTCT 1984
- TSHA 2019
- Country
- NTCT United States
- TSHA United States
- Employees
- NTCT N/A
- TSHA N/A
- Industry
- NTCT EDP Services
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- NTCT Technology
- TSHA Health Care
- Exchange
- NTCT Nasdaq
- TSHA Nasdaq
- Market Cap
- NTCT 1.6B
- TSHA 1.4B
- IPO Year
- NTCT 1999
- TSHA 2020
- Fundamental
- Price
- NTCT $26.86
- TSHA $4.96
- Analyst Decision
- NTCT Buy
- TSHA Strong Buy
- Analyst Count
- NTCT 2
- TSHA 9
- Target Price
- NTCT $29.00
- TSHA $10.00
- AVG Volume (30 Days)
- NTCT 430.4K
- TSHA 11.4M
- Earning Date
- NTCT 11-06-2025
- TSHA 11-04-2025
- Dividend Yield
- NTCT N/A
- TSHA N/A
- EPS Growth
- NTCT N/A
- TSHA N/A
- EPS
- NTCT 1.02
- TSHA N/A
- Revenue
- NTCT $834,861,000.00
- TSHA $8,098,000.00
- Revenue This Year
- NTCT $5.30
- TSHA N/A
- Revenue Next Year
- NTCT $2.68
- TSHA N/A
- P/E Ratio
- NTCT $26.61
- TSHA N/A
- Revenue Growth
- NTCT 5.29
- TSHA N/A
- 52 Week Low
- NTCT $18.12
- TSHA $1.05
- 52 Week High
- NTCT $27.89
- TSHA $5.51
- Technical
- Relative Strength Index (RSI)
- NTCT 61.35
- TSHA 59.93
- Support Level
- NTCT $26.53
- TSHA $4.70
- Resistance Level
- NTCT $26.83
- TSHA $5.08
- Average True Range (ATR)
- NTCT 0.50
- TSHA 0.35
- MACD
- NTCT 0.03
- TSHA -0.07
- Stochastic Oscillator
- NTCT 85.35
- TSHA 49.16
About NTCT NetScout Systems Inc.
NetScout Systems Inc is a provider of service assurance and cybersecurity solutions to enterprise and government networks. It bases its solutions on proprietary adaptive service intelligence technology, which helps customers monitor and identify performance issues and provides insight into network-based security threats. These solutions also deliver real-time and historical information, which provides insight to restore service and understand the quality of user experience. The company derives revenue from the sale of network management tools and security solutions. Its geographical regions include USA, which derives maximum revenue, Europe, Asia, and Rest of the World.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.